Literature DB >> 17850143

Bifunctional amine-tethered ruthenium(II) arene complexes form monofunctional adducts on DNA.

Michael Melchart1, Abraha Habtemariam, Olga Novakova, Stephen A Moggach, Francesca P A Fabbiani, Simon Parsons, Viktor Brabec, Peter J Sadler.   

Abstract

The tethered RuII half-sandwich complexes [eta(6):eta(1)-C(6)H(5)(CH(2))(n)NH(2))RuCl(2)] 1 (n = 3) and 2 (n = 2) have been synthesized as potential bifunctional anticancer complexes, and their X-ray crystal structures have been determined. They hydrolyze rapidly in aqueous solution to give predominantly mono-aqua mono-chlorido species. Mono-9EtG adducts, where 9EtG = 9-ethylguanine, form rapidly, but the second 9EtG binds more slowly and more weakly. In the X-ray crystal structure of the di-9EtG adduct [(eta(6):eta(1)-C(6)H(5)(CH(2))(3)NH(2))Ru(9EtG)2](CF(3)SO(3))(2).H(2)O (8.H(2)O), one of the Ru-N7 bonds is significantly longer than the other (2.1588(18) vs 2.101(2) A). The bound guanine bases adopt a head-to-head configuration, stabilized by tether NH2 hydrogen bonding to C6O of 9EtG. The X-ray crystal structure of the dinitrato complex [(eta(6):eta(1)-C(6)H(5)(CH(2))(3)NH(2))Ru(NO(3))(2)] (3) showed both nitrates to be bound to ruthenium. This complex readily rutheniated calf thymus DNA but failed to produce stop sites on pSP73KB plasmid DNA during DNA transcription by an RNA polymerase. This suggested that only monofunctional DNA adducts formed, as did interstrand cross-linking assays. Also, the unwinding angle induced in negatively supercoiled DNA (9 +/- 1 degrees) was less than that induced by cisplatin (13 degrees). These findings may explain why complexes such as 1 and 2 exhibited low cytotoxicities (IC(50) values >100 microM) toward A2780 human ovarian cancer cells.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17850143     DOI: 10.1021/ic700799w

Source DB:  PubMed          Journal:  Inorg Chem        ISSN: 0020-1669            Impact factor:   5.165


  7 in total

Review 1.  Unusual DNA binding modes for metal anticancer complexes.

Authors:  Ana M Pizarro; Peter J Sadler
Journal:  Biochimie       Date:  2009-04-01       Impact factor: 4.079

2.  Synthesis, characterization, and in vitro antimalarial and antitumor activity of new ruthenium(II) complexes of chloroquine.

Authors:  Chandima S K Rajapakse; Alberto Martínez; Becky Naoulou; Andrzej A Jarzecki; Liliana Suárez; Christiane Deregnaucourt; Véronique Sinou; Joseph Schrével; Elgilda Musi; Grazia Ambrosini; Gary K Schwartz; Roberto A Sánchez-Delgado
Journal:  Inorg Chem       Date:  2009-02-02       Impact factor: 5.165

3.  Bipyrimidine ruthenium(II) arene complexes: structure, reactivity and cytotoxicity.

Authors:  Soledad Betanzos-Lara; Olga Novakova; Robert J Deeth; Ana M Pizarro; Guy J Clarkson; Barbora Liskova; Viktor Brabec; Peter J Sadler; Abraha Habtemariam
Journal:  J Biol Inorg Chem       Date:  2012-07-12       Impact factor: 3.358

4.  Controlling Platinum, Ruthenium and Osmium Reactivity for Anticancer Drug Design.

Authors:  Pieter C A Bruijnincx; Peter J Sadler
Journal:  Adv Inorg Chem       Date:  2009-07-07       Impact factor: 3.282

5.  Organometallic cis-Dichlorido Ruthenium(II) Ammine Complexes.

Authors:  Soledad Betanzos-Lara; Abraha Habtemariam; Guy J Clarkson; Peter J Sadler
Journal:  Eur J Inorg Chem       Date:  2011-06-22       Impact factor: 2.524

6.  Direct formation of tethered Ru(II) catalysts using arene exchange.

Authors:  Rina Soni; Katherine E Jolley; Guy J Clarkson; Martin Wills
Journal:  Org Lett       Date:  2013-09-26       Impact factor: 6.005

7.  Cytotoxic effects of the compound cis-tetraammine(oxalato)ruthenium(III) dithionate on K-562 human chronic myelogenous leukemia cells.

Authors:  Flávia de Castro Pereira; Aliny Pereira de Lima; Cesar Augusto Sam Tiago Vilanova-Costa; Wanessa Carvalho Pires; Alessandra de Santana Braga Barbosa Ribeiro; Lucas Carlos Gomes Pereira; Luiz Alfredo Pavanin; Wagner Batista Dos Santos; Elisângela de Paula Silveira-Lacerda
Journal:  Springerplus       Date:  2014-06-19
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.